loader2
Login Open ICICI 3-in-1 Account
Open ICICI 3-in-1 Account

Krishna Institute of Medical Sciences Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Krishna Institute of Medical Sciences Ltd. 07 Nov 2025 17:58 PM
Result PDF

Q2FY26 Quarterly Result Announced for Krishna Institute of Medical Sciences Ltd.

Healthcare Facilities company Krishna Institute of Medical Sciences announced Q2FY26 results

  • Total Revenue of Rs 965 crore, a growth of 23.3% on YoY and 9.8% on QoQ basis.
  • EBITDA of Rs 208 crore, a de growth of 6.7% on YoY and a growth of 4.3% on QoQ basis.
  • EBITDA margin at 21.6% vs. 28.5% in Q2FY25 and 22.7% in Q1FY26.
  • PAT at Rs 72 crore in Q2FY26 against Rs 121 crore and Rs 85 crore in Q2FY25 and Q1FY26 respectively.
  • Consolidated EPS for Q2FY26 of Rs 1.67, a degrowth of 37.7% on YoY basis and 14.7% QoQ respectively.
  • Cash and Cash Equivalents (includes Cash, Bank balance, Deposits with maturity less than 12 months and Investment in Mutual funds) at Rs 120 crore as on 30th September 2025.

B Bhaskar Rao, CMD, KIMS Hospitals, said: "Q2FY26 has been a busy quarter for us. We have seen patient footfalls steadily increasing at all our centers. I am particularly pleased that our newly opened unit at Thane has seen very good traction and completed 1000 surgeries in less than 6 months of operations. Our Bangalore unit at Mahadevpura also went live this quarter. I am optimistic that the remaining half of FY26 will help us achieve our targets set."

Result PDF

Result PDF

Healthcare Facilities company Krishna Institute of Medical Sciences announced Q1FY26 results

  • Total revenue of Rs 879 crore, a growth of 26.8% on YoY and 9.6% on QoQ basis.
  • EBITDA of Rs 200 crore, a growth of 8.5% on YoY and a de growth of 1.4% on QoQ basis.
  • EBITDA margin at 22.7% vs. 26.6% in Q1FY25 and 25.3% in Q4FY25.
  • PAT at Rs 85 crore in Q1FY26 against Rs 95 crore and Rs 106 crore in Q1FY25 and Q4FY25 respectively.
  • Consolidated EPS for Q1FY26 of Rs 1.96, a degrowth of 9.2% on YoY basis.
  • Cash and Cash Equivalents (includes Cash, Bank balance, Deposits with maturity less than 12 months and Investment in Mutual funds) at Rs 70 crore as on Q1FY26.

B Bhaskar Rao, CMD, KIMS Hospitals, said: “Q1FY26 has started on a robust note with all engines performing optimally. Despite being a seasonally lean quarter, we have managed to grow on key parameters. Patient footfalls have seen a good uptick in all units especially in new one like Thane. I am optimistic that we are on track to meet our targets for FY26. Our 2 units of Bangalore will be commencing in Q2.”

Result PDF

Healthcare Facilities company Krishna Institute of Medical Sciences announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • Total revenue of Rs 801 crore, a growth of 25.7% on YoY and 1.4% on QoQ basis.
  • EBITDA of Rs 203 crore, a growth of 24.4% on YoY and a de-growth of 1.2% on QoQ basis.
  • EBITDA margin at 25.3% vs. 25.5% in Q4FY24 and 25.9% in Q3FY25.
  • PAT at Rs 106 crore in Q4FY25 against Rs 72 crore and Rs 93 crore in Q4FY24 and Q3FY25 respectively.
  • Consolidated EPS for FY25 of Rs 9.6, a growth of 24.0% on YoY basis.
  • Cash and Cash Equivalents (includes Cash, Bank balance, Deposits with maturity less than 12 months and Investment in Mutual funds) at Rs 102 crore as on Q4FY25.

FY25 Financial Highlights:

  • Total revenue of Rs 3,067 crore, a growth of 22.0% on YoY basis.
  • EBITDA of Rs 815 crore, a growth of 24.7% on YoY basis.
  • EBITDA margin at 26.6% vs. 26.0% in FY24.
  • PAT at Rs 415 crore in FY25 against Rs 336 crore in FY24.

Announcing Q4FY25 results, B Bhaskar Rao, CMD, KIMS Hospitals, said: "FY25 has been an excellent year on multiple fronts for us. We added new units across geographies including newer ones like Kerala. Our mission to provide affordable and accessible quality healthcare is finding resonance and acceptance across stakeholders. We have commenced operations at Thane in April, 2025 and we will be opening 2 units in Bangalore in H1 FY26.

Result PDF

Healthcare Facilities company Krishna Institute of Medical Sciences announced Q3FY25 results

  • Gross revenue of Rs 790 crore, a growth of 29.7% on YoY and 1.0% on QoQ basis.
  • EBITDA of Rs 205 crore, a growth of 36.4% on YoY and de growth of 8.1% on QoQ basis.
  • EBITDA margin at 25.9% vs 24.7% in Q3FY24 and 28.5% in Q2FY25.
  • PAT at Rs 93 crore in Q3FY25 against Rs 77 crore and Rs 121 crore in Q3 FY24 and Q2FY25 respectively.
  • Consolidated EPS for 9 months of Rs 7.1 (face value of shares Rs 2/-), a growth of 15.6% (adjusted for share split) on YoY basis.
  • Cash and Cash Equivalents (includes Cash, Bank balance, Deposits with maturity less than 12 months and Investment in Mutual funds) at Rs 112 crore as on Q3FY25.

B Bhaskar Rao, CMD, KIMS Hospitals, said: “Despite being a seasonally lean quarter, we have managed growth on key parameters like ARBOB and ARPP on a YoY basis. This has been possible because of our relentless focus on improving operational efficiencies. Going forward, as new units starts delivering on all parameters, we are confident of achieving our targets set for FY25 and beyond”.

Result PDF

Healthcare Facilities company Krishna Institute of Medical Sciences announced Q2FY25 results

  • Gross revenue of Rs 782 crore, a growth of 19.4% on YoY and 12.9% on QoQ basis.
  • EBITDA of Rs 223 crore, a growth of 23.8% on YoY and 21.2% on QoQ basis.
  • EBITDA margin at 28.5% vs. 27.5% in Q2FY24 and 26.6% in Q1FY25.
  • EBITDA Margin (excluding Other Income) stands at 28.1% vs. 27.2% in Q2FY24 and 26.1% in Q1FY25.
  • PAT at Rs 121 crore in Q2FY25 against Rs 101 crore and Rs 95 crore in Q2FY24 and Q1FY25 respectively.
  • Consolidated EPS of Rs 3, a growth of 16.7% on YoY and 24.0% on QoQ basis.
  • Cash and Cash Equivalents (includes Cash, Bank balance, Deposits with maturity less than 12 months and Investment in Mutual funds) at Rs 90 crore as on Q2FY25.

B Bhaskar Rao, CMD, KIMS Hospitals, said: The second quarter has been an extremely busy and productive one on multiple fronts for us. Our unit in Nashik went live this quarter and we are happy to say that we have started our first hospital in Kerala at Kannur. All our units are working to their optimal capacity to meet the rush of patients across all geographies. We have been focusing on ensuring that our mission to provide affordable and accessible quality healthcare reaches everyone effectively. We are confident and on track to achieve our targets for FY25."

Result PDF

Healthcare Facilities company Krishna Institute of Medical Sciences announced Q1FY25 results:

Financial Highlights:

  • Consolidated Revenue from Operations grew by 13.6% on a YoY and 8.6% on a QoQ basis to Rs 688 crore
  • Consolidated EBITDA (Pre-INDAS) declined by 0.4% on a YoY and grew by 0.9% on a QoQ basis to 176.6 crore
  • Consolidated EBITDA (Pre-INDAS and excluding Other Income) Margin stands at 25.0%, a decrease of 0.6% YoY and growth of 0.9% QoQ.
  • Gross revenue of Rs 693 crore, a growth of 13.8% on YoY and 8.7% on QoQ basis.
  • EBITDA of Rs 184 crore, a growth of 14.9% on YoY and 13.0% on QoQ basis.
  • EBITDA margin at 26.6% vs. 26.3% in Q1 FY24 and 25.5% in Q4 FY24.
  • EBITDA Margin (excluding Other Income) stands at 26.1%, a growth of 0.1% on YoY and 1.0% on QoQ.
  • PAT at Rs 95.1 crore in Q1 FY25 against Rs 86.7 crore and Rs 71.6 crore in Q1 FY24 and Q4 FY24 respectively.
  • Consolidated EPS of Rs 10.8, a growth of 7.0% on YoY and 32.1% on QoQ basis.
  • Bed occupancy in Q1 FY25 at 49.8%, declined by 3.2% on YoY and 1.7% QoQ basis.
  • Cash and Cash Equivalents (includes Cash, Bank balance, Deposits with maturity less than 12 months and Investment in Mutual funds) at Rs 185 crore in Q1 FY25.

Operational Highlights:

  • ARPOB grew by 21.3% and 12.2% on YoY and QoQ basis respectively
  • ARPP grew by 6.1% and 1.4% on YoY and QoQ basis respectively
  • IP Volume grew by 7.5% and 7.1% on YoY and QoQ basis respectively
  • Conducted 4.2 lakhs OPD consults in Q1 FY25, which grew by 10.2% on YoY and 2.6% on QoQ basis.

Announcing Q1 FY 25 results, B Bhaskar Rao, CMD, KIMS Hospitals, said: FY 25 has begun on a robust note. Most of our units have performed as per targets, especially the newer ones of Nagpur and Sunshine. Clinical additions to key departments over the last few quarters have helped us serve our patients better and add to our topline too. Nashik unit will be operational this quarter and we are excited by the clinical talent that has come on board. I am optimistic that we are on track to achieve our targets for FY 25.

Result PDF

Healthcare Facilities company Krishna Institute of Medical Sciences announced Q4FY24 & FY24 results:

  • Gross revenue at Rs 6376 million, an increase of 9.8% on YoY and 4.7% on QoQ basis.
  • EBITDA of Rs 1628 million, a decline of 3.2% on YoY and growth by 8.3% on QoQ basis.
  • EBITDA margin in Q4FY24 stood at 25.5% vs. 28.9% in Q4 FY23 and 24.7% in Q3 FY24.
  • EBITDA (excluding Other Income) Margin stands at 25.1%, showing a decline of 3.2% on YoY and an increase of 0.8% on QoQ.
  • PAT at Rs 716 million in Q4FY24 against Rs 987 million and Rs 767 million in Q4 FY23 and Q3 FY24 respectively.
  • Consolidated EPS declined by 29.8% on YoY and 8.8% on QoQ basis to Rs 8
  • Bed occupancy in Q4FY24 at 51.4%*, a decline by 1.7% on YoY and 2.8% QoQ basis. [*As per the industry standard, % occupancy is mentioned as % to bed capacity, rather than % to census beds, from this quarter]
  • Cash and Cash Equivalents at Rs 132 crore as at 31st March, 2024. Net Debt to Equity ratio at 0.44

Announcing Q4 results, Dr. B Bhaskar Rao, CMD, KIMS Hospitals, said: Over all FY 24 has been a clinically and financially a good year for us. I am particularly pleased that our newly acquired units of Sunshine and Nagpur have shown good momentum. I am confident that FY25 will see robust growth with our new unit coming up at Nashik in Q1FY25 & Thane and Bangalore units getting operationalized by the end of FY25”

Result PDF

Healthcare Facilities company Krishna Institute of Medical Sciences announced Q3FY24 results:

  • Gross revenue at Rs 609 crore for the Q3FY24, an increase of 7.1% on a YoY and a decrease of 7.1% on a QoQ basis.
  • Reported operating EBITDA of Rs 150 crore for the Q3FY24, a decrease of 4.6% YoY and 16.5% QoQ basis.
  • Reported EBITDA margin at 24.7% vs. 27.7% in Q3FY23 and 27.5% in Q2FY24.
  • PAT at Rs 77 crore in Q3FY24 against Rs 82 crore and Rs 101 crore in Q3FY23 and Q2FY24 respectively.
  • Conducted 3.92 lakh OPD consults in Q3FY24, up by 2.7% on YoY and decreased by 7.3% on QoQ basis.
  • Bed occupancy in Q3FY24 at 72.2%, up by 3.9% on YoY and down by 4.2% QoQ basis.
  • ARPOB decreased marginally to Rs 30,741 in Q3FY24, a 3.1% increase YoY and 1.3% decrease on QoQ basis.
  • Cash and Cash Equivalents at Rs 105 crore in Q3FY24.Net Debt to Equity ratio at 0.33

Announcing Q3 results, Dr. B Bhaskar Rao, CMD, KIMS Hospitals, said: “ We have seen a dip in patient footfalls this quarter. Traditionally, this happens to be slack season on account of festivals. Besides, the cyclone in Andhra Pradesh and assembly elections in Telangana have shown some impact. But I am particularly pleased to see that all our units have continued to produce excellent clinical outcomes. We should be opening our Nashik unit in Q1FY25. I am optimistic that we are on track to achieve our targets for FY24.”

 

Result PDF

Healthcare Facilities company Krishna Institute of Medical Sciences announced Q2FY24 results:

  • Gross revenue at Rs 655 crore, a growth of 14.3% on a YoY and 7.6% on a QoQ basis.
  • Reported Operating EBITDA of Rs 180 crore, an increase of 11.5% YoY and 12.5% QoQ basis.
  • Reported EBITDA margin at 27.5% vs. 28.3% in Q2FY23 and 26.3% in Q1FY24.
  • PAT at Rs 101 crore in Q2FY24 against Rs 91 crore (before one-offs) and Rs 87 crore in Q2FY23 and Q1FY24 respectively.
  • Conducted 4.13 lakhs OPD consults in Q2FY24, up by 10% on YoY and 8% on QoQ basis.
  • Bed occupancy in Q2FY24 at 76.4%, up by 3.8% on YoY and 6% QoQ basis.
  • ARPOB at Rs 31,140 in Q2FY24, 6.5% growth YoY and marginal decline of 1.8% on QoQ basis.
  • Cash and Cash Equivalents at Rs 104 crore in Q2FY24.
  • Net Debt to Equity ratio at 0.26.

Announcing Q2FY24 results, Dr. B Bhaskar Rao, CMD, KIMS Hospitals, said, "The second quarter has been a busy one for us. We have seen patient footfalls steadily increasing at all our centers. I am particularly pleased to see that our clinical additions in the newly acquired units (Sunshine & Nagpur) have resulted in an uptick in performances across all fronts. Our expansion plans at Bangalore, Nashik and Mumbai are progressing as per schedule. I am optimistic that we are on track to achieve our targets for FY24.

 

Result PDF

Healthcare Facilities company Krishna Institute of Medical Sciences announced Q1FY24 results:

  • Gross revenue at Rs 609 crore, a growth of 21.6% on a YoY and 4.9% on a QoQ basis.
  • Operating EBITDA of Rs 160 crore, an increase of 12.4% YoY and a decrease of 4.7% QoQ basis.
  • EBITDA margin at 26.3% vs. 28.5% in Q1FY23 and 28.9% in Q4FY23.
  • PAT at Rs 87 crore in Q1FY24 against Rs 79 crore and Rs 99 crore in Q1FY23 and Q4FY23 respectively.
  • Conducted 3.83 lakh OPD consults in Q1FY24, up by 18% and 0.4% YoY and QoQ basis.
  • Bed occupancy in Q1FY24 at 70.4%, up by 5% on YoY and down by 0.4% on QoQ basis.
  • ARPOB increased to Rs 31,697 in Q1FY24 showing 5.0% growth YoY and 3.7% growth QoQ basis.
  • Cash and Cash Equivalents at Rs 178 crore in Q1FY24.
  • Net Debt to Equity ratio at 0.22.

Announcing Q1FY24 results, Dr. B Bhaskar Rao, CMD, KIMS Hospitals, said, “The first quarter of FY24 has started on a robust note with all engines performing optimally. Despite it being a seasonally lean quarter, we have done reasonably well on key parameters. I am particularly happy to note that the integration efforts of our recently acquired assets have started seeing fruition. We continue to focus on two critical parameters: Clinical Excellence and Affordable Quality Care. I am optimistic that we are on track to meet our targets for FY24”.

 

 

Result PDF

Trending News

Saregama India's announced strategic partnership with, and investment in, Sanjay Leela Bhansali's Bhansali Productions

Saregama India's announced strategic partnership with, and investment in, Sanjay Leela Bhansali's Bhansali Productions

Published on 17-Dec-2025 09:01

The Competition Commission of India (CCI) has approved ITC’s acquisition of the paper and pulp manufacturing business of Aditya Birla Real Estate Ltd (ABREL).

The Competition Commission of India (CCI) has approved ITC’s acquisition of the paper and pulp manufacturing business of Aditya Birla Real Estate Ltd (ABREL)

Published on 17-Dec-2025 09:00

Zydus Lifesciences has received a USFDA acceptance for its ANDA of for copper histidinate (CUTX-101), intended to treat Menkes disease in pediatric patients.

Zydus Lifesciences has received a USFDA acceptance for its ANDA of for copper histidinate (CUTX-101), intended to treat Menkes disease in pediatric patients.

Published on 16-Dec-2025 09:05

KIMS has commenced operations at its newly established hospital located at the PES University campus in Electronic City, Bengaluru

Krishna Institute of Medical Sciences (KIMS) has commenced operations at its newly established hospital located at the PES University campus in Electronic City, Bengaluru

Published on 16-Dec-2025 09:03

Power Grid Corporation of India Ltd (POWERGRID) has been declared the successful bidder under Tariff-Based Competitive Bidding

Power Grid Corporation of India Ltd (POWERGRID) has been declared the successful bidder under Tariff-Based Competitive Bidding 

Published on 16-Dec-2025 09:01

Marico is in talks to acquire Cosmix, a startup that sells plant-based protein supplements

Marico is in talks to acquire Cosmix, a startup that sells plant-based protein supplements

Published on 16-Dec-2025 09:00

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app
✕
Application status